Effects of sevoflurane vs. propofol on mitochondrial functional activity after ischemia-reperfusion injury and the influence on clinical parameters in patients undergoing CABG surgery with cardiopulmonary bypass

Perfusion (United Kingdom)

Volumn 30, Issue 7, 2015, Pages 590-595

  Sirvinskas, E ^a,b   Kinderyte, A ^a   Trumbeckaite, S ^a   Lenkutis, T ^a   Raliene, L ^a,b   Giedraitis, S ^a   Macas, A ^a   Borutaite, V ^a  

^a LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

^b LITHUANIAN UNIVERSITY OF HEALTH SCIENCES   (Lithuania)

Author keywords

anesthetics; cardioprotection; ischemic reperfusion injury; mitochondrial function; preconditioning

Indexed keywords

CYTOCHROME C; PROPOFOL; SEVOFLURANE; TROPONIN I; BIOLOGICAL MARKER; ETHER DERIVATIVE;

AGED; ARTICLE; ARTIFICIAL VENTILATION; BREATHING RATE; CARDIOPULMONARY BYPASS; CONTINUOUS INFUSION; CONTROLLED STUDY; CORONARY ARTERY BYPASS SURGERY; FEMALE; HEART MITOCHONDRION; HEART PROTECTION; HUMAN; HUMAN CELL; HUMAN TISSUE; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OUTER MEMBRANE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REPERFUSION INJURY; ADVERSE EFFECTS; COMPARATIVE STUDY; CORONARY ARTERY BYPASS GRAFT; METABOLISM; MIDDLE AGED; MYOCARDIAL REPERFUSION INJURY; PATHOLOGY; PROCEDURES;

AGED; BIOMARKERS; CARDIOPULMONARY BYPASS; CORONARY ARTERY BYPASS; FEMALE; HUMANS; MALE; METHYL ETHERS; MIDDLE AGED; MITOCHONDRIA, HEART; MYOCARDIAL REPERFUSION INJURY; PROPOFOL;

EID: 84942588261     PISSN: 02676591     EISSN: 1477111X     Source Type: Journal    
DOI: 10.1177/0267659115571174     Document Type: Article

References (22)

1. Ferdinandy P, Schulz R, Baxter GF,. Interaction of cardiovascular risk factors with myocardial ischemia/reperfusion injury, preconditioning, and postconditioning. Pharmacol Rev 2007; 59: 418-458.
2. Shimokawa H, Yasuda S,. Myocardial ischemia: current concepts and future perspectives. J Cardiol 2008; 52: 67-78.
3. Parlakpinar H, Orum MH, Sagir M,. Pathophysiology of myocardial ischemia reperfusion injury: a review. Med Science 2013; 2: 935-954.
4. Swyers T, Redford D, Larson DF,. Volatile anesthetic-induced preconditioning. Perfusion 2013; 29: 10-15.
5. Loveridge R, Schroeder F,. Anesthetic preconditioning. Contin Educ Anaesth Crit Care Pain 2010; 10: 38-42.
6. Zaugg M, Lucchinetti E, Uecker M, et al. Anaesthetics and cardiac preconditioning. Part I. Signalling and cytoprotective mechanisms. Br J Anaesth 2003; 91: 551-565.
7. Kwok WM, Aizawa K,. Preconditioning of the myocardium by volatile anesthetics. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 249-255.
8. Yu CH, Beattie WS,. The effects of volatile anesthetics on cardiac ischemic complications and mortality in CABG: a meta-analysis. Can J Anaesth 2006; 53: 906-912.
9. Yao YT, Li LH,. Sevoflurane versus propofol for myocardial protection in patients undergoing coronary artery bypass grafting surgery: a meta-analysis of randomized controlled trials. Chin Med Sci J 2009; 24: 133-141.
10. Lutz M, Liu H,. Inhaled sevoflurane produces better delayed myocardial protection at 48 versus 24 hours after exposure. Anesth Analg 2006; 102: 984-990.
11. Torri G,. Inhalation anesthetics: a review. Minerva Anestesiol 2010; 76: 215-228.
12. Lorsomradee S, Cromheecke S, De Hert SG,. Cardioprotection with volatile anesthetics in cardiac surgery. Asian Cardiovasc Thorac Ann 2008; 16: 256-264.
13. De Ruijter W, Musters RJ, Boer C, et al. The cardioprotective effect of sevoflurane depends on protein kinase C activation, opening of mitochondrial K(+)(ATP) channels, and the production of reactive oxygen species. Anesth Analg 2003; 97: 1370-1376.
14. Yvon A, Hanouz JL, Haelewyn B, et al. Mechanisms of sevoflurane-induced myocardial preconditioning in isolated human right atria in vitro. Anesthesiology 2003; 99: 27-33.
15. Mullenheim J, Ebel D, Frassdorf J, et al. Isoflurane preconditions myocardium against infarction via release of free radicals. Anesthesiology 2002; 96: 934-940.
16. Erturk E,. Ischemia-reperfusion injury and volatile anesthetics. Biomed Res Int 2014; 2014: 526301.
17. Pravdic D, Mio Y, Sedlic F, et al. Isoflurane protects cardiomyocytes and mitochondria by immediate and cytosol-independent action at reperfusion. Br J Pharmacol 2010; 160: 220-232.
18. Symons JA, Myles PS,. Myocardial protection with volatile anaesthetic agents during coronary artery bypass surgery: a meta-analysis. Br J Anaesth 2006; 97: 127-136.
19. Lange M, Redel A, Smul TM, et al. Desflurane-induced preconditioning has a threshold that is lowered by repetitive application and is mediated by beta2-adrenergic receptors. J Cardiothorac Vasc Anaesth 2009; 23: 607-613.
20. Pantos C, Mourouzis I, Cokkinos DV,. Protection of the abnormal heart. Heart Fail Rev 2007; 12: 319-330.
21. Mio Y, Bienengraeber MW, Stadnicka A, et al. Age-related attenuation of isoflurane preconditioning in human atrial cardiomyocytes: roles for mitochondrial respiration and sarcolemmal adenosine triphosphate-sensitive potassium channel activity. Anesthesiology 2008; 108: 612-620.
22. Abete P, Ferrara N, Cioppa A, et al. Tandem action of exercise training and food restriction completely preserves ischemic preconditioning in the aging heart. Exp Gerontol 2005; 40: 43-50.